EN DE
Watch CK Life Sciences Intl Holdings Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CK Life Sciences Intl Holdings Inc (0775) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CK Life Sciences Intl Holdings Inc stock HK$0.53, price HK$0.54, that is 0.3% below the price, quality 31 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN KYG2176J1058

CL CK Life Sciences Intl Holdings Inc logo Thin data Nov 10, 2026

CK Life Sciences Intl Holdings Inc

0775 · HK
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Ranks above peers (8/11)
Fair value HK$0.5334 · Fairly valued
Moderate debt
Quality 31/100
Weak Growth (revenue 5y +1.8 %/yr in HKD)
Loss-making · -1.2% net margin (TTM)
Negative free cash flow
Narrow moat 16/100 · thin data
Thin data
Estimate
Watch CK Life Sciences Intl Holdings Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$1.21 HK$0.3100 Fair Value HK$0.5334 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range HK$0.3100 – HK$1.21 · fair‑value band HK$0.4001 – HK$0.6668 · the HK$0.5350 price screens above the HK$0.5334 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CK Life Sciences Intl Holdings in your weekly email

Every Wednesday you see whether CK Life Sciences Intl Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America.

Show moreShow less

It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, trades, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines.

The company is also involved in the contract manufacturing of complementary healthcare medicines; supplies raw materials in nutritional health, pharmaceutical, cosmetics, personal care and food segments; financing activities; holding land and buildings; investment in financial instruments and vineyards; trading of biotechnology products and nutritional supplements; and manufacturing, wholesaling, retailing, and distribution of nutraceutical products.

In addition, the company distributes turf management machinery, hardware, equipment, and accessories, as well as turf fertilizers, chemicals, and professional pest products; and produces, refines, and distributes salt products.

Further, it researches, develops, manufactures, and commercializes drug products to treat pain and melanoma; develops novel nonopioid therapeutics; supplies raw materials for nutritional health, pharmaceutical, cosmetics, personal care, and food sectors; and offers packing and asset management services.

The company was founded in 1999 and is headquartered in Tai Po, Hong Kong.

Stock analysis

CK Life Sciences Intl Holdings Inc (0775) currently trades at HK$0.5350, while our estimate is HK$0.5334, so the stock looks roughly fairly valued today (gap 0.3%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.4001 (bear) to HK$0.6668 (bull), the price of HK$0.5350 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

CK Life Sciences Intl Holdings Inc reported revenue of HK$5.4B in FY2025 versus HK$5.4B in FY2021, a compound +0.0%/yr. Reported net income was −HK$188M in FY2025.

Key figures

Market cap HK$5.1B (≈ $655M) Small · P/S ratio 0.84 · Net margin −1.2% · Return on equity −2.2% · Return on assets (EBIT) 2.4% (5-year average) · Operating margin 3.2% · Revenue (TTM) HK$5.5B · Revenue growth (YoY) +4.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 0%, 0775 screens cheaper than that median.

Fair Value

Bear HK$0.4001 Fair Value HK$0.5334 Bull HK$0.6668
Price HK$0.5350 · Downside -0.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 16
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 19
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−2.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Start year 2020 (pandemic). Over 10 years: +1.0% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.7% (2020) → −2.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 0775, get fair value alerts →

Compare CK Life Sciences Intl Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −0.3% · Top 25%
Profitability
Return on assets −1.6% · Above median
Net margin (12 months) −1.2% · Above median
Operating margin (12 months) 3.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 4.2% · Above median
Balance sheet
Debt / equity 0.97× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.36× · Cheaper than median
P/S (12 months) 0.93× · Cheapest 25%
EV/EBITDA 53.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 0
FUTURE (revenue growth)21 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)52 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 0775
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 0775
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 0775
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 0775
argenx SE ARGX $971.55 $908.40 −7% vs 0775
CSL Limited CSL A$201.68 A$181.40 −10% vs 0775
Moderna, Inc MRNA $250.83 $158.70 −37% vs 0775
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 0775
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 0775
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 0775

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CK Life Sciences Intl Holdings Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CK Life Sciences Intl Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/0775

Frequently asked questions

Is CK Life Sciences Intl Holdings Inc (0775) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.5334 versus a price of HK$0.5350, about 0% lower (fairly valued).
What is the fair value of 0775?
Our estimate for CK Life Sciences Intl Holdings Inc is HK$0.5334 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.5350.
What is the quality score of 0775?
CK Life Sciences Intl Holdings Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CK Life Sciences Intl Holdings Inc (0775)?
Our calculated price target is the estimate of HK$0.5334 (as of Nov 10, 2026). Cautious scenario HK$0.4001, optimistic scenario HK$0.6668. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CK Life Sciences Intl Holdings Inc stock forecast for 2026?
Our estimate puts fair value at HK$0.5334, about 0% lower versus a price of HK$0.5350 (fairly valued). Cautious scenario HK$0.4001, optimistic scenario HK$0.6668. The calculation is refreshed regularly with new filings.
What is the revenue of CK Life Sciences Intl Holdings Inc (0775)?
CK Life Sciences Intl Holdings Inc reported trailing-twelve-month revenue of about HK$5.5B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CK Life Sciences Intl Holdings Inc (0775)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CK Life Sciences Intl Holdings Inc it is HK$0.5334 per share (as of Nov 10, 2026), against a price of HK$0.5350.
Is CK Life Sciences Intl Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 0775 trades above its calculated fair value: price HK$0.5350, fair value HK$0.5334, a gap of about −0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0775?
No. The price is what the market pays today (HK$0.5350); the fair value is what the company's own numbers justify (HK$0.5334). For CK Life Sciences Intl Holdings Inc the two are HK$0.0016 per share apart. That gap is exactly why we show both numbers side by side.
How much is CK Life Sciences Intl Holdings Inc worth?
The market values CK Life Sciences Intl Holdings Inc at about HK$5.1B (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.5350; our models calculate a fair value of HK$0.5334 per share.
What do the bullish and bearish scenarios say about 0775?
Our models span a range for CK Life Sciences Intl Holdings Inc: cautious scenario HK$0.4001, base HK$0.5334, optimistic HK$0.6668 per share (as of Nov 10, 2026, price HK$0.5350). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CK Life Sciences Intl Holdings Inc (0775)?
Balance-sheet figures for CK Life Sciences Intl Holdings Inc (as of Nov 10, 2026): return on equity −2.2%, debt of 0.97 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 0775 from its 52-week high?
CK Life Sciences Intl Holdings Inc trades at HK$0.5350, about 47% below its 52-week high of HK$1.01 and 10% above the low of HK$0.4850 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.5334 is for.
Which stocks are comparable to CK Life Sciences Intl Holdings Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CK Life Sciences Intl Holdings Inc stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.5350, calculated fair value HK$0.5334 (−0%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CK Life Sciences Intl Holdings Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CK Life Sciences Intl Holdings Inc (0775)?
The closing price on Nov 10, 2026 was HK$0.5350. Our estimate is HK$0.5334, about 0% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CK Life Sciences Intl Holdings Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of CK Life Sciences Intl Holdings Inc

How large is the market capitalisation of CK Life Sciences Intl Holdings Inc (0775)?
The market capitalisation of CK Life Sciences Intl Holdings Inc is HK$5.1B (≈ $655M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CK Life Sciences Intl Holdings Inc (0775)?
The price-to-sales ratio of CK Life Sciences Intl Holdings Inc is 0.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of CK Life Sciences Intl Holdings Inc (0775)?
The net margin of CK Life Sciences Intl Holdings Inc is −1.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CK Life Sciences Intl Holdings Inc (0775)?
The return on equity (ROE) of CK Life Sciences Intl Holdings Inc is −2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CK Life Sciences Intl Holdings Inc (0775)?
On an EBIT basis the return on assets of CK Life Sciences Intl Holdings Inc is 2.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CK Life Sciences Intl Holdings Inc (0775)?
The operating margin of CK Life Sciences Intl Holdings Inc is 3.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CK Life Sciences Intl Holdings Inc (0775)?
Revenue at CK Life Sciences Intl Holdings Inc is growing +4.2% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CK Life Sciences Intl Holdings Inc (0775)?
Earnings per share at CK Life Sciences Intl Holdings Inc are growing −97.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CK Life Sciences Intl Holdings Inc (0775) generate?
The free cash flow of CK Life Sciences Intl Holdings Inc is −HK$278M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CK Life Sciences Intl Holdings Inc (0775) carry?
The net debt of CK Life Sciences Intl Holdings Inc is HK$6.0B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CK Life Sciences Intl Holdings Inc in the live analysis

One click puts CK Life Sciences Intl Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.